IPO Pipeline Meets Regulatory Rewire as SEC Rewrites Market Plumbing

The IPO market and the rules that govern how those new shares trade are both being rewritten at the same moment. That coincidence is not accidental — it is the product of a market that surged back to life in the first half of 2026 and a commission that has decided the plumbing needs to catch up.

The Issuance Wave by the Numbers

Renaissance Capital counts 93 IPOs priced year-to-date (deals with a market cap of at least $50 million), raising $144.0 billion in total proceeds — a 631.4% jump from the same point last year, even as deal count is down 24.4%.^[1] Filing activity is also running ahead, with 155 new IPO filings logged, up 10.7% year-over-year. SPACs account for 134 of the year’s offerings, the largest single bucket by sector.^[1]

The second quarter alone saw 48 IPOs, led by SpaceX’s record $75 billion deal at a $1.7 trillion market cap. Even excluding that outlier, nine other IPOs raised $1 billion or more, a cadence that Morgan Stanley has described as a broader and deeper market than the 2021 cycle.^[2]

This Week: Four Pricings, Mixed Receptions

The week of July 28 brought four IPOs to market, and the results were uneven — a useful signal about where investor appetite actually sits.

Jersey Mike’s Subs (JMKE) — The Blackstone-backed sandwich chain priced 43.5 million shares at $23, the midpoint of its $21–$25 range, raising $1.0 billion. Sixty-eight percent of the offer was secondary stock from existing holders.^[3] The stock opened at $21, 8.7% below the offer price, and closed its first session down 5.7%.^[3] For a profitable, franchised consumer brand with more than 3,000 locations, that discount is a data point worth watching: the market is not automatically rewarding growth stories at IPO pricing.

Reformation (REF) — The Permira-backed sustainable womenswear brand priced 14.06 million shares at $15, the low end of its $15–$17 range, raising $210.9 million.^[4] The stock was roughly flat on its first day of NYSE trading.^[4]

Apnimed (APMD) — A late-stage biotech developing an oral therapy for sleep apnea, Apnimed upsized its deal to 12 million shares at $16, the high end of its $14–$16 range, raising $192 million.^[5] The upsizing and high-end pricing suggest institutional demand for clinical-stage pharma is firmer than for consumer retail — a divergence that aligns with what the broader IPO data shows.

Ionic Digital (IOND) — A Bitcoin mining company that listed on Nasdaq on July 28 with roughly 10.8 million shares, bringing the crypto-adjacent sector back into the IPO mix.^[2]

Next Week’s Pipeline

Two of the three are biotech names, continuing the sector’s dominance in the mid-cap pipeline. No deals are currently scheduled beyond next week — IPO dates are rarely set more than 7–10 days in advance.^[6]

Goldman’s Late-Cycle Question

On July 28, Goldman Sachs Research published “IPO Surge: A Red Flag for Markets?” — asking whether the record issuance pace is flashing a late-cycle warning sign and whether the market can comfortably digest the supply.^[7] The report weighs two concerns: that surging IPO volume has historically correlated with equity market peaks, and that new supply could pressure valuations even if the cycle is not ending. Goldman’s prior analysis in June concluded that the current surge has not reached dot-com-era euphoria levels, though the bank is not dismissing the risk.^[7]

This is the right frame for the question. The IPO market is not a bubble indicator in isolation — the 2021 cycle showed that heavy issuance can persist for quarters before a correction — but the combination of rising supply and mixed first-day performance (Jersey Mike’s discount, Reformation at the low end) is a pattern worth tracking. If more deals begin pricing below range or withdrawing, that would be a more meaningful signal than headline deal count.

The Regulatory Rewire

While the IPO window is open, the SEC is simultaneously reengineering the infrastructure those new shares will trade on. Three developments in the last seven weeks stand out.

1. Proposed Rescission of Rule 611 (Trade-Through Rule)

On June 11, 2026, the SEC proposed rescinding Rule 611 of Regulation NMS — the order protection or “trade-through” rule that has required brokers to route orders to the best displayed price across all venues since 2005. The proposal would also rescind Rule 610(e), which prohibits locked and crossed markets.^[8]

SEC Chairman Paul Atkins, who opposed Rule 611 since its adoption, argued the rule has driven venue fragmentation rather than encouraging displayed liquidity.^[9] Industry voices like T. Rowe Price’s global head of equity trading have echoed that view, calling the rule redundant in an automated market and arguing it protects commercial venues at the expense of market users.^[9]

The risk, as buy-side participants have flagged, is that removing protected-quote status could lead to further fragmentation if firms rely on different data feeds to calculate their own best bid and offer. A market-share threshold for participation in the Securities Information Processor has been proposed as a way to preserve a standardized benchmark without the trade-through prohibition.^[9]

2. 24-Hour Trading Roundtable

On July 23, the SEC announced a public roundtable on September 17, 2026, to discuss moving U.S. equity markets toward 24-hour trading, including overnight operations, resiliency, and investor protections.^[10] Chairman Atkins framed the move as aligning U.S. markets with international exchanges that already trade on a continuous schedule.^[10] The roundtable is open to the public and will be streamed live, with public comments accepted under File Number 4-913.

3. Texas Stock Exchange Auction Approval

The Texas Stock Exchange (TXSE) commenced live trading on July 10, 2026, after receiving SEC approval in September 2025, with a phased symbol rollout from test securities to National Market System stocks.^[11] On July 24, the SEC approved TXSE’s proposed rule change for its opening and closing auction mechanics (Release No. 34-105988), giving the new national securities exchange the infrastructure to compete for the critical opening and closing crosses that anchor institutional order flow.^[11]

Global Pipeline: Unitree Tests the Robot Valuation Benchmark

In China, Unitree Robotics launched its IPO process on Shanghai’s STAR Market with a target of raising roughly $620 million (4.4 billion yuan), with subscription set for August 10.^[12] Unitree, known for its humanoid and quadruped robots, would become the first pure-play robotics company to set a public valuation benchmark — a listing that could shape how global investors price the humanoid robotics category. The offering proceeds against a backdrop of a U.S. ban on certain Unitree products, adding a geopolitical dimension to the valuation test.^[12]

What to Watch Next

• Jersey Mike’s first-week close. If JMKE remains below its $23 offer price through the first five sessions, it will reinforce the pattern of institutional caution on consumer-franchise IPOs. A recovery above $23 would suggest the opening discount was a technical artifact.
• August biotech pricings. Attovia and Braveheart Bio are both pricing in the $15–$17 range. Biotech has been the strongest IPO sub-sector for pricing power; if either deal prices below range, it would be the first crack in that thesis.
• SEC comment period on Rule 611. The proposal is open for public comment. The tone and volume of buy-side and exchange comments will signal how contentious final adoption will be. Watch for whether major exchanges submit competing data-feed proposals.
• TXSE market share. The first full month of TXSE trading data will show whether the new exchange is capturing meaningful volume or operating as a marginal venue. Opening and closing auction participation is the metric to watch.
• Goldman’s digestion question. The supply test is not whether IPOs price — they are pricing — but whether secondary markets absorb them. First-week performance across the cohort is a cleaner signal than headline deal count.

The base case is that the IPO window stays open through the third quarter and the regulatory changes proceed on their proposed timelines. But the 40% tail includes a scenario where mixed first-day performance narrows the window for consumer and lower-quality deals before the SEC’s structural changes take effect — meaning some issuers may face a choice between accepting lower valuations now or waiting for a regulatory landscape that could be materially different by year-end.